Poor warfarin dose prediction with pharmacogenetic algorthms that exclude genotypes important for African Americans

Pharmacogenetics and Genomics

Volumn 25, Issue 2, 2015, Pages 73-81

  Drozda, Katarzyna ^a   Wong, Shan ^a   Patel, Shitalben R ^a   Bress, Adam P ^a   Nutescu, Edith A ^a   Kittles, Rick A ^a   Cavallari, Larisa H ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

CYP2C9; genotype; pharmacogenomics; rs12777823; warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 2C9;

ADULT; AFRICAN AMERICAN; ALGORITHM; ALLELE; ARTICLE; BODY SURFACE; CHEEK CELL; CONTROLLED STUDY; CYP2C9 11 GENE; CYP2C9 5 GENE; CYP2C9 6 GENE; CYP2C9 8 GENE; DEEP VEIN THROMBOSIS; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; DOSE CALCULATION; DOSE RESPONSE; GENETICS; MIDDLE AGED; PROCEDURES; PROGNOSIS;

ADULT; AFRICAN AMERICANS; AGED; ALGORITHMS; ANTICOAGULANTS; CYTOCHROME P-450 CYP2C9; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; WARFARIN;

EID: 84920880030     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000108     Document Type: Article

References (39)

1. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5:615-621.
2. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784-792.
3. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7:99-111.
4. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90:625-629.
5. International Warfarin Pharmacogenetics Consortium. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-764.
6. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84:326-331.
7. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369:2294-2303.
8. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369:2283-2293.
9. Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulous VG, Verhoef TI, Wadelius M, et al. EU-PACT Study Group. Patients benefit from geneticsguided coumarin anticoagulant therapy. Clin Pharmacol Ther 2014; 96:15-17.
10. Scott SA, Lubitz SA. Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics 2014; 15:719-722.
11. Cavallari LH, Kittles RA, Perera MA. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014; 370:1763.
12. Daneshjou R, Klein TE, Altman RB. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014; 370:1762-1763.
13. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F. EU-PACT Study Group. A proposal for an individualized pharmacogeneticsbased warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther 2011; 90:701-706.
14. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112:1022-1027.
15. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5:e1000433.
16. Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in underrepresented minority groups. Future Cardiol 2012; 8:563-576.
17. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C95) expressed among African Americans. Mol Pharmacol 2001; 60:382-387.
18. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. Clin Appl Thromb Hemost 2004; 10:149-154.
19. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (8) polymorphism. Clin Pharmacol Ther 2012; 91:660-665.
20. Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CL, Rettie AE. In-vitro and in-vivo effects of the CYP2C911 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 2005; 15:475-481.
21. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9:511-526.
22. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:459-464.
23. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013; 382:790-796.
24. Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AF, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J 2014; 14:223-228.
25. Cavallari LH, Vaynshteyn D, Freeman KM, Wang D, Perera MA, Takahashi H, et al. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C98-mediated effects. Pharmacogenet Genomics 2013; 23:228-231.
26. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011; 89:408-415.
27. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 2010; 12:283-291.
28. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C98 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009; 10:1243-1255.
29. Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 2013; 13:369-377.
30. Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, Hiratsuka M. Functional characterization of CYP2C9 allelic variants. Pharmacogenomics J 2014; 14:107-114.
31. Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012; 13:407-418.
32. Bristol-Myers Squibb. Coumadin (warfarin sodium) package insert. Princeton, NJ: Bristol-Myers Squibb; 2010.
33. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 2011; 12:953-963.
34. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698.
35. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83:312-321.
36. Biss TT, Avery PJ, Williams MD, Brandão LR, Grainger JD, Kamali F. The VKORC1 and CYP2C9 genotypes are associated with over-Anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost 2013; 11:373-375.
37. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-Analysis. J Thromb Haemost 2014; 12:1480-1487.
38. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:445-451.
39. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 2012; 12:417-424.